Clinical Trial Update: Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating maintenance therapy with olaparib or selumetinib in combination with durvalumab for metastatic pancreatic adenocarcinoma, guided by BRC…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Koselugo (selumetinib)
• Lynparza (olaparib)

Snippet

Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group | Conditions: Metastatic Pancreatic Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING